Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | 31.16% | 12.92% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -2.20% | 16.25% | |
| Operating Income | -- | -- | 2.20% | -16.25% | |
| Income Before Tax | -- | -- | 3.10% | -6.73% | |
| Income Tax Expenses | -- | -- | -333.71% | 136.13% | |
| Earnings from Continuing Operations | -- | -- | 5.55% | -20.74% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | 5.55% | -20.74% | |
| EBIT | -- | -- | 2.20% | -16.25% | |
| EBITDA | -- | -- | 2.71% | -15.89% | |
| EPS Basic | -- | -- | 21.73% | 4.04% | |
| Normalized Basic EPS | -- | -- | 20.33% | 15.57% | |
| EPS Diluted | -- | -- | 21.73% | 4.04% | |
| Normalized Diluted EPS | -- | -- | 20.33% | 15.57% | |
| Average Basic Shares Outstanding | -- | -- | 22.03% | 27.71% | |
| Average Diluted Shares Outstanding | -- | -- | 22.03% | 27.71% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |